GlaxoSmithKline Stock News Today

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Report: 22nd of July 2020  

GlaxoSmithKline Stock News module provides quick insight into current market opportunities from investing in GlaxoSmithKline PLC. Use historical and current headlines to determine the investment entry and exit points. Many technical investors use GlaxoSmithKline PLC stock news signals to limit their universe of possible portfolio assets and to time the market correctly. Please check GlaxoSmithKline PLC Hype Analysis, GlaxoSmithKline PLC Correlation and GlaxoSmithKline PLC Performance.

Search Today's Stock News

 
Refresh
GlaxoSmithKline PLC stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of GlaxoSmithKline daily returns and investor perception about the current pice of GlaxoSmithKline PLC as well as its diversification or hedging effects on your existing portfolios.
  
2 days ago at www.marketbeat.com         
GlaxoSmithKline plc Insider Purchases 128.80 in Stock - MarketBeat
Marketbeat News
GlaxoSmithKline plc Insider Purchases 128.80 in Stock MarketBeat
  
  
3 days ago at simplywall.st         
What Kind Of Shareholders Own Orchard Therapeutics plc - Simply Wall St
Simply Wall St News at Macroaxis
What Kind Of Shareholders Own Orchard Therapeutics plc Simply Wall St
  
  
few days ago at finance.yahoo.com         
Is GlaxoSmithKlines Dividend Enough to Offset Its Slowing Cash Flow - Yahoo Finance
Yahoo News
Is GlaxoSmithKlines Dividend Enough to Offset Its Slowing Cash Flow Yahoo Finance
  
  
over a week ago at primefeed.in         
Multivalent Vaccines Market Leading 10 Key-Players Revenue, Shares, Sales and Forecasts Till 2026 CO...
P
Multivalent Vaccines Market Leading 10 Key-Players Revenue, Shares, Sales and Forecasts Till 2026 COVID19 Impact Analysis GlaxoSmithKline, plc , Pfizer, Inc. , Merck Co., etc. InForGrowth Owned
  
  
over a week ago at money.yahoo.com         
Cramer Welcomes 3 Stocks To His COVID-19 Index, Kicks Out 3 Others - Yahoo Money
Yahoo News
Cramer Welcomes 3 Stocks To His COVID-19 Index, Kicks Out 3 Others Yahoo Money
  
  
over two weeks ago at www.nasdaq.com         
GlaxoSmithKline Stock Moves -1. percent What You Should Know - Nasdaq
nasdaq News
GlaxoSmithKline Stock Moves -1. percent What You Should Know Nasdaq
  
  
over two weeks ago at www.nasdaq.com         
Mercks Pneumococcal Vaccine Meets Goal in Two Adult Studies - Nasdaq
nasdaq News
Mercks Pneumococcal Vaccine Meets Goal in Two Adult Studies Nasdaq
  
  
over two weeks ago at www.nasdaq.com         
Childrens Cough Syrups Recalled For Faulty Dosing Cups - Nasdaq
nasdaq News
Childrens Cough Syrups Recalled For Faulty Dosing Cups Nasdaq
  
  
over three weeks ago at finance.yahoo.com         
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision M...
Yahoo News
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology Yahoo Finance
  
  
over three weeks ago at www.directorstalkinterviews.com         
GlaxoSmithKline PLC - Consensus Indicates Potential 18.6 percent Upside - DirectorsTalk Interviews
D
GlaxoSmithKline PLC - Consensus Indicates Potential 18.6 percent Upside DirectorsTalk Interviews
  
  
over a month ago at medicinsider.com         
Lidocaine Patches Market Worldwide Analysis with Acorda Therapeutics, ALLERGAN, Endo International, ...
M
Lidocaine Patches Market Worldwide Analysis with Acorda Therapeutics, ALLERGAN, Endo International, GlaxoSmithKline plc. Medic Insider
  
  
over a month ago at www.nasdaq.com         
Drugmakers Target Coronavirus Vaccine in 2020 4 Stocks in Focus - Nasdaq
nasdaq News
Drugmakers Target Coronavirus Vaccine in 2020 4 Stocks in Focus Nasdaq
  
  
over a month ago at www.bnnbloomberg.ca         
AstraZeneca said to approach Gilead about potential merger - BNNBloomberg.ca
bloomberg News
AstraZeneca said to approach Gilead about potential merger BNNBloomberg.ca
  
  
over a month ago at www.directorstalkinterviews.com         
GlaxoSmithKline PLC - Consensus Indicates Potential 13.2 percent Upside - DirectorsTalk Interviews
D
GlaxoSmithKline PLC - Consensus Indicates Potential 13.2 percent Upside DirectorsTalk Interviews
  
  
over a month ago at moneymorning.com         
How Is the Economy Doing Short- and Long-Term Economic Impacts of COVID-19 - Money Morning
M
How Is the Economy Doing Short- and Long-Term Economic Impacts of COVID-19 Money Morning
  

Investors are also looking into

GlaxoSmithKline PLC Performance against DOW

 Price Growth (%)  
      Timeline 
1
Vaccines Market Landscape to 2027 by Type, Technology, Disea...04/22/2020
2
Move Over, FAANGs. Goldman Unveils Europes GRANOLAS Stocks -...04/28/2020
3
Other04/29/2020
4
Other04/30/2020
5
Other05/01/2020
6
Other05/04/2020
7
Pound slumps after construction sector sees worst decline on...05/06/2020
8
Other05/07/2020
9
Other05/11/2020
10
Other05/12/2020
11
Huge Sales Growth Brightens Future for Amarin Stock - 247 Wa...05/13/2020
12
Other05/18/2020
13
Other05/19/2020
14
Other05/26/2020
15
Glaxo to Make 1 Billion Doses of Pandemic Vaccine Booster - ...05/28/2020
16
Other06/01/2020
17
Unclassified Event06/04/2020
18
Other06/09/2020
19
Other06/11/2020
20
Other06/16/2020
21
Other06/17/2020
22
Other06/18/2020
23
Other06/19/2020
24
Unclassified Event06/22/2020
25
Mercks Pneumococcal Vaccine Meets Goal in Two Adult Studies ...06/23/2020
26
Other06/29/2020
27
Multivalent Vaccines Market Leading 10 Key-Players Revenue, ...07/01/2020
28
GlaxoSmithKline plc Insider Purchases 128.80 in Stock - Mark...07/10/2020
Please check GlaxoSmithKline PLC Hype Analysis, GlaxoSmithKline PLC Correlation and GlaxoSmithKline PLC Performance. Please also try Fund Screener module to find activelly-traded funds from around the world traded on over 30 global exchanges.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page